SGLT2 Inhibitors Benefit Broad Range of Heart Failure Patients
FRIDAY, Sept. 2, 2022 (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitors cut the risk for cardiovascular death and hospitalization for heart failure in patients with heart failure, regardless of ejection fraction, according to a study published online Aug. 27 in The Lancet to coincide with the European Society of Cardiology Congress 2022, held from Aug. 26 to 29 in Barcelona, Spain.
Muthiah Vaduganathan, M.D., from Brigham and Women’s Hospital in Boston, and colleagues conducted a meta-analysis using data from the DELIVER and EMPEROR-Preserved clinical trials (12,251 participants) to assess therapeutic effects of SGLT2 inhibitors on patients with heart failure and mildly reduced or preserved ejection fraction.
The researchers found that SGLT2 inhibitors reduced composite cardiovascular death or first hospitalization for heart failure (hazard ratio [HR], 0.80; 95 percent confidence interval [CI], 0.73 to 0.87), with consistent reductions seen in both components (cardiovascular death: HR, 0.88; 95 percent CI, 0.77 to 1.00; first hospitalization for heart failure: HR, 0.74; 95 percent CI, 0.67 to 0.83). When examining additional data across five trials (21,947 participants), SGLT2 inhibitors reduced the risk for composite cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality with or without mildly reduced or preserved ejection fraction.
“SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalizations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting,” the authors write.